Stem-cell chairman takes on wider role
By Carl T. Hall,
San Francisco Chronicle
| 01. 07. 2005
Board names Klein president, gives him authority to hire staff
Robert N. Klein, the Palo Alto developer and stem-cell advocate, took on the crucial day-to-day management duties Thursday for California's $3 billion stem-cell program.
Klein, who already was serving as chairman of the 29-member oversight board directing the voter-approved California Institute for Regenerative Medicine, was named by that board to be interim president of the institute with authority to hire staff and find office space.
State voters created the institute in November by passing Proposition 71, which authorized up to $350 million a year in taxpayer-financed bonds to pay for research projects and facilities during the next decade. The main purpose of the grants will be to promote embryonic stem-cell research that can't be financed by the federal government under rules adopted by the Bush administration.
Stem cells are the early, undifferentiated cells that eventually turn into the many specific cell types of the body. Biologists say the cells are invaluable research tools that might be fashioned into cures for diseases that can't otherwise be treated effectively. Religious and other...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...